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Tumors arising at the lacrimal sac are extremely rare, as a limited number of cases have
been reported worldwide.They are commonly primary and the majority of them are malig-
nant and epithelial in origin. Adenocarcinomas account for a small percentage of these
tumors. Treatment of local disease mainly includes complete surgical resection. However,
metastatic disease has a poor prognosis and the development of new treatment strategies
is highly important. Research efforts mainly focus on the identification of molecular targets
for therapy. Herein, we describe for the first time a case of a patient with an androgen
receptor expressing adenocarcinoma of the lacrimal sac that had an impressive response
to abiraterone.
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BACKGROUND
The tumors of the lacrimal drainage system are extremely rare as
approximately 400 cases have been reported in the literature to
date (1–3). The lacrimal sac is the upper dilated end of the naso-
lacrimal duct formed by the lacrimal bone and the frontal process
of the maxilla (2).
Tumors arising at the lacrimal sac are usually primary. Most of
these tumors are malignant (75%) and of epithelial origin (70%)
including squamous cell carcinoma, transitional cell carcinoma,
mucoepidermoid, adenoid cystic, poorly differentiated carcinoma,
and adenocarcinoma. The non-epithelial histologies include lym-
phoma, histiocytoma, sarcoma, hemangiopericytoma, malignant
melanoma, and neurofibroma (4). Secondary tumors usually arise
from adjacent organs (orbit, paranasal sinuses). Mortality rate
depends on histology and stage. Early detection and treatment
are very important for this category of tumors (5).
Lacrimal sac tumors usually present with symptoms such as
epiphore, dacryocystitis, and pain with or without associated
tumor mass. Differential diagnosis includes infection or inflam-
matory lesions (dacryocystitis, tuberculosis, fungal infections,
Wegener’s granuloma, or sarcoidosis). CT and MRI of the head and
neck are required for the evaluation of the size of the tumor mass,
the extent of the invasion into the adjacent structures and assess-
ment of regional lymph node status. Chest imaging is also required
at diagnosis as these tumors often metastasize to the lungs (6).
With the exception of lymphomas, lacrimal sac carcinomas
should be treated with complete surgical removal of the tumor
with wide excision to achieve clear margins. Resection of adja-
cent structures and lymph node dissection may be required in
more extensive disease (2). For epithelial tumors, post-operative
radiotherapy is usually recommended (5). Local recurrence may
be treated with surgery, radiotherapy, or chemotherapy. Metastatic
disease is associated with a very poor prognosis. In the era of mol-
ecular targeted therapies, new therapeutic approaches are under
evaluation (2, 3, 5). In this report, we present a case of impressive
response of an androgen receptor (AR) expressing lacrimal sac
adenocarcinoma to abiraterone.
CASE PRESENTATION
In May 2007, a 65-year-old man was diagnosed with locally
advanced lacrimal cyst adenocarcinoma. The patient presented
with dacryorrhea and 3 months later, he developed a right parotid
mass and multiple enlarged cervical lymph nodes. He under-
went a complete surgical resection including right ophthalmus,
right parotid gland, and lymph node dissection. Biopsy revealed
a lacrimal sac adenocarcinoma with positive surgical margins.
Post-operative radiotherapy was administered (50 Gy) with con-
comitant administration of weekly cisplatin at a dose of 35 mg/m2.
Baseline CEA level before surgical resection was not evaluated.
After surgical resection, CEA level was 13 mg/L.
Two years later, he developed recurrence manifested with
extensive superficial cutaneous involvement of the right cervi-
cal area. Biopsy confirmed recurrence of a lacrimal sac adeno-
carcinoma. The tumor cells were positive for EGFR (3+), AR
(strongly positive) HER-2 expression (2+) by immunohistochem-
istry. FISH was positive for HER-2 amplification. Six cycles of car-
boplatin/docetaxel/trastuzumab were administered every 3 weeks
between May and September of 2009. The patient attained a par-
tial response (PR), which was short-lived. Two months following
completion of chemotherapy, the patient had disease progression
with appearance of new cutaneous lesions. Second line chemother-
apy with eight cycles of cisplatin/pemetrexed/bevacizumab every
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3 weeks was administered between November 2009 and April 2010.
A complete clinical and radiological remission was achieved and
maintenance therapy with bevacizumab was given until disease
progression.
Six months after completion of cisplatin/pemetrexed and beva-
cizumab triplet and while on bevacizumab maintenance, the
patient developed new cutaneous nodules at the right neck
area, which were positive for adenocarcinoma on fine nee-
dle aspiration. Third line chemotherapy with weekly carbo-
platin/paclitaxel/cetuximab was initiated. Following the admin-
istration of a single dose, the patient developed grade III mucosal
toxicity and grade IV diarrhea that led to omission of cetuximab
in subsequent treatment cycles. After four cycles of chemother-
apy, the patient was deemed to have PR and a decision was made
for him to discontinue chemotherapy and proceed to electron
beam radiotherapy, which was administered between February
and March 2011.
In April 2012,a PET–CT identified osteoblastic bone metastasis.
Administration of afatinib and zolendronic acid was begun. After
4 months of treatment, afatinib was discontinued due to disease
progression, which involved presence of new cutaneous nodules
in the right zygomatic area and soft tissue mass in the temporal
area. In January 2013, the patient presented to our hospital for the
first time for a second opinion. Due to AR positivity, treatment
with bicalutamide and LHRH was begun. The patient displayed
PR to androgen ablation, which was manifested as size reduction of
the temporal mass and decline in CEA level (from 13 to 10 mg/L),
which was unfortunately short-lived, as it lasted for only 2 months.
In August 2013, bicalutamide was substituted by abiraterone
(1000 mg daily) plus prednisolone (10 mg daily), while LHRH
analog was continued. Disease evaluation at 3 months revealed
a good clinical response with disappearance of cutaneous lesions
and a decrease in size of the temporal soft tissue mass, as well
as a substantial biochemical response (CEA level dropped from
10 to 4 mg/L). After 6 months of treatment, the patient had a
complete response according to RECIST criteria, with resolution
of cutaneous lesions and temporal soft tissue mass (Figure 1).
At the last follow-up in August 2014, clinical, biochemical, and
imaging evaluation showed no evidence of disease progression
and the patient was continued on abiraterone/LHRH treatment.
DISCUSSION
Herein, we describe for the first time a case of adenocarcinoma of
the lacrimal sac treated successfully with abiraterone. Abiraterone
inhibits 17 α-hydroxylase/C17,20 lyase (CYP17A1), an enzyme
mainly expressed in testicular, adrenal, and prostatic tumor tis-
sues. More specifically, CYP17 catalyzes two sequential reactions;
the conversion of pregnenolone and progesterone to their 17-α-
hydroxy derivatives by its hydroxylase activity, and the subsequent
formation of dehydroepiandrosterone (DHEA) and androstene-
dione, respectively, by its lyase activity. DHEA and androstene-
dione are androgens and precursors of testosterone. As a result,
inhibition of CYP17 activity by abiraterone decreases circulating
levels of testosterone (7). Abiraterone is approved by both Food
and Drug Administration (FDA) and European Medicines Agency
(EMA) in combination with prednisone for treatment of patients
with metastatic castration-resistant prostate cancer.
FIGURE 1 | Complete resolution of temporal soft tissue mas after six
months of treatment with abiraterone.
Tumors of the lacrimal sac are very rare and heterogeneous.
Surgical resection is the backbone of treatment when a total resec-
tion of the tumor is feasible. Radiotherapy and chemotherapy
may be added. When a tumor recurs locally or distantly and
surgery or radiotherapy is not therapeutic options, systemic ther-
apy can be considered. However, administration of chemotherapy
is anecdotal and has been disappointing (2).
Adenocarcinomas constitute a small percentage of tumors of
the lacrimal sac. These are rare tumors and research efforts focus
on identification of molecular targets for therapy. In our case, the
tumor was found to be AR positive. This is in concordance with
one previous report (8). Other molecular targets for therapy may
include HER-2 and mTOR (8, 9).
The lacrimal and salivary glands share similar characteristics.
Lacrimal sac adenocarcinomas may originate from seromucinous
glands in the lacrimal sac. These glands constitute of serous and
mucinous units and have been found to be similar in salivary gland
and lacrimal sac (10). Furthermore, salivary gland type neoplasms,
such as adenoid cystic carcinoma, mucoepidermoid carcinoma,
and pleomorphic adenoma, have been reported in the lacrimal sac
and these tumors might arise from the seromucinous glands in
the lacrimal sac (2–4). Therefore, salivary gland and lacrimal sac
tumors might be of the same origin.
Androgen-deprivation therapy consisting of bicalutamide and
LHRH analog has been repeatedly reported to be an effec-
tive treatment option for AR+ adenocarcinomas of the salivary
glands (11–13). In 2003, Locati et al. first described a patient
with AR expressing salivary gland adenocarcinoma who experi-
enced a complete remission 2 months after receiving complete
anti-androgen blockade with LHRH analog and bicalutamide
(11). More recently, Soper et al. reported a case of a patient
with locally advanced AR positive salivary duct carcinoma who
had a long-term complete remission shortly after administra-
tion of androgen-deprivation therapy (12). Similarly, a case of
a patient with a metastatic AR-positive salivary duct carcinoma
who had an impressive response with bicalutamide has been
reported (13). However, the experience with abiraterone is limited
in this setting. In a recent report by Locati et al., abiraterone
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showed remarkable activity in two patients with AR express-
ing recurrent and metastatic salivary gland carcinoma (14). In
our case, complete anti-androgen blockade with bicalutamide
plus LHRH was chosen as the optimal therapy at the time,
based on AR expression of the tumor and reported literature
on salivary gland carcinomas. Treatment resulted in partial,
albeit short-lived response. However, the patient demonstrated an
impressive long-lasting response to abiraterone plus prednisolone,
which is still ongoing. Interestingly, response to abiraterone
was strikingly better to previously administrated chemother-
apy, although the patient was heavily pretreated. The choice of
abiraterone as appropriate treatment was based on AR signal-
ing and the model of prostate cancer. The genetic background
of the tumor underlying this response including the dissection
of the molecular events of the androgen signaling pathway is
worth exploring.
Of note, potential side effects of abiraterone are concerning,
since grade 3 or 4 adverse events have been reported in almost 25%
of patients in large randomized trials (15). Coadministration with
the recommended dose of glucocorticoid prednisone compensates
for abiraterone-induced reductions in serum cortisol and blocks
the compensatory increase in adrenocorticotropic hormone seen
with abiraterone (16). In general, glucocorticoid-related adverse
events tend to occur at doses and/or treatment durations greater
than the low dose of glucocorticoid approved in combination with
abiraterone acetate.
In the era of molecular targeted therapy, we recommend for all
recurrent/metastatic epithelial lacrimal sac tumors to be tested for
AR positivity. Potential administration of androgen-deprivation
therapy or abiraterone to female patients with AR expressing
tumors is intriguing. A randomized study for assessment of effec-
tiveness of abiraterone in lacrimal sac tumors is warranted, albeit
extremely difficult to realize due to rarity of the tumor.
CONCLUDING REMARKS
In conclusion, androgen-deprivation therapy including the new
anti-androgens such as abiraterone and enzalutamide may prove
effective treatment options for AR+ lacrimal gland tumors.
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